Interestingly, a meta-analysis from 2018 documented the possibility of protective properties of incretin drugs against pancreatic cancer in T2DM patients who followed incretin-based antidiabetic treatment ≥ 104 weeks (OR 0.62; 95% CI 0.41–0.95) [58]. The gene discussed is GCG; the disease is familial pancreatic carcinoma.